Patterns of Computed Tomography Surveillance in Survivors of Colorectal Cancer at Veterans Health Administration Facilities

被引:7
作者
Sehdev, Amikar [1 ,2 ,3 ]
Sherer, Eric A. [4 ,5 ]
Hui, Siu L. [2 ]
Wu, Jingwei [6 ]
Haggstrom, David A. [2 ,5 ,7 ]
机构
[1] Indiana Univ Sch Med, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA
[2] Regenstrief Inst Hlth Care, Ctr Hlth Serv Res, Indianapolis, IN USA
[3] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA
[4] Louisiana Tech Univ, Dept Chem Engn, Ruston, LA 71270 USA
[5] Hlth Serv Res & Dev Serv, Vet Hlth Adm, Dept Vet Affairs, Ctr Hlth Informat & Commun, Indianapolis, IN USA
[6] Temple Univ, Coll Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19122 USA
[7] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA
关键词
colorectal cancer (CRC); computed tomography (CT); guideline-concordant care; overuse; quality; surveillance; veterans; FOLLOW-UP CARE; AMERICAN-SOCIETY; COLON-CANCER; ADJUVANT CHEMOTHERAPY; PRACTICE GUIDELINE; 5-YEAR SURVIVAL; RADICAL SURGERY; RISK-FACTORS; MANAGEMENT; QUALITY;
D O I
10.1002/cncr.30569
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Annual computed tomography (CT) scans are a component of the current standard of care for the posttreatment surveillance of survivors of colorectal cancer (CRC) after curative-intent resection. The authors conducted a retrospective study with the primary aim of assessing patient, physician, and organizational characteristics associated with the receipt of CT surveillance among veterans. METHODS: The Department of Veterans Affairs Central Cancer Registry was used to identify patients diagnosed with AJCC collaborative stage I to III CRC between 2001 and 2009. Patient sociodemographic and clinical (ie, CRC stage and comorbidity) characteristics, provider specialty, and organizational characteristics were measured. Hierarchical multivariable logistic regression models were used to assess the association between patient, provider, and organizational characteristics on receipt of 1) consistently guideline-concordant care (at least 1 CT every 12 months for both of the first 2 years of CRC surveillance) versus no CT receipt and 2) potential overuse (> 1 CT every 12 months during the first 2 years of CRC surveillance) of CRC surveillance using CT. The authors also analyzed the impact of the 2005 American Society of Clinical Oncology update in CRC surveillance guidelines on care received over time. RESULTS: For 2263 survivors of stage II/III CRC who were diagnosed after 2005, 19.4% of patients received no surveillance CT, whereas potential overuse occurred in both surveillance years for 14.9% of patients. Guideline-concordant care was associated with younger age, higher stage of disease (stage III vs stage II), and geographic region. In adjusted analyses, younger age and higher stage of disease (stage III vs stage II) were found to be associated with overuse. There was no significant difference in the annual rate of CT scanning noted across time periods (year <= 2005 vs year>2005). CONCLUSIONS: Among a minority of veteran survivors of CRC, both underuse and potential overuse of CT surveillance were present. Patient factors, but no provider or organizational characteristics, were found to be significantly associated with patterns of care. The 2005 change in American Society of Clinical Oncology guidelines did not appear to have an impact on rates of surveillance CT. (C) 2017 American Cancer Society.
引用
收藏
页码:2338 / 2351
页数:14
相关论文
共 60 条
[1]  
American Cancer Society, KEY STAT COL CANC
[2]  
[Anonymous], NCCN GUID VERS 3
[3]  
[Anonymous], FOLL CAR SURV PROT S
[4]  
[Anonymous], IMPR CAR QUAL LIF CA
[5]  
[Anonymous], FED PRACT
[6]  
[Anonymous], PQD ADJ CANC
[7]   Association of managed care market share and health expenditures for fee-for-service Medicare patients [J].
Baker, LC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (05) :432-437
[8]  
Bazzoli GJ, 1999, HEALTH SERV RES, V33, P1683
[9]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[10]   Localized Colon Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines [J].
Benson, Al B., III ;
Bekaii-Saab, Tanios ;
Chan, Emily ;
Chen, Yi-Jen ;
Choti, Michael A. ;
Cooper, Harry S. ;
Engstrom, Paul F. ;
Enzinger, Peter C. ;
Fakih, Marwan G. ;
Fenton, Moon J. ;
Fuchs, Charles S. ;
Grem, Jean L. ;
Hunt, Steven ;
Kamel, Ahmed ;
Leong, Lucille A. ;
Lin, Edward ;
May, Kilian Salerno ;
Mulcahy, Mary F. ;
Murphy, Kate ;
Rohren, Eric ;
Ryan, David P. ;
Saltz, Leonard ;
Sharma, Sunil ;
Shibata, David ;
Skibber, John M. ;
Small, William, Jr. ;
Sofocleous, Constantinos T. ;
Venook, Alan P. ;
Willett, Christopher G. ;
Gregory, Kristina M. ;
Freedman-Cass, Deborah A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (05) :519-528